The purpose of this study was to assess the relation between maternal multivitamin use and risk for cardiac defects in the offspring, using a population-based approach. The Atlanta Birth Defects Case-Control study is a population-based case-control study of infants born between 1968 and 1980 to mothers residing in metropolitan Atlanta, Georgia. The 958 case infants with nonsyndromic cardiac defects were actively ascertained from multiple sources. The 3,029 infants without birth defects (control infants) were selected from birth certificates by stratified random sampling. Periconceptional multivitamin use, defined as reported regular use of multivitamins from 3 months before pregnancy through the first 3 months of pregnancy, was contrasted with no use during the same time period. Periconceptional multivitamin use was associated with a reduced risk for nonsyndromic cardiac defects in the offspring (odds ratio (OR) = 0.76; 95% confidence interval (CI): 0.60, 0.97). The risk reduction was strongest lor outflow tract defects (OR = 0.46; 95% CI: 0.24, 0.86) and ventricular septal defects (OR = 0.61; 95% CI: 0.38, 0.99). No risk reduction was evident when multivitamin use was begun after the first month of pregnancy. If these associations are causal, the results suggest that approximately one in four major cardiac defects could be prevented by periconceptional multivitamin use. Am J Epidemio/2000; 151 :878-84.
stratified random sampling. Periconceptional multivitamin use, defined as reported regular use of multivitamins from 3 months before pregnancy through the first 3 months of pregnancy, was contrasted with no use during the same time period. Periconceptional multivitamin use was associated with a reduced risk for nonsyndromic cardiac defects in the offspring (odds ratio (OR) = 0.76; 95% confidence interval (CI): 0.60, 0.97). The risk reduction was strongest lor outflow tract defects (OR = 0.46; 95% CI: 0.24, 0.86) and ventricular septal defects (OR = 0.61; 95% CI: 0.38, 0.99). No risk reduction was evident when multivitamin use was begun after the first month of pregnancy. If these associations are causal, the results suggest that approximately one in four major cardiac defects could be prevented by periconceptional multivitamin use. Am J Epidemio/2000; 151 :878-84.
abnormalities; heart defects, congenital; heart septal defects, ventricular; vitamins Cardiac defects. which affect at least one in ISO newborns, are the most common group of major congenital anomalies (1) (2) (3) (4) (5) . Cardiac defects are also a major cause of infant mortality due to congenital anomalies (6) , and they impose a considerable burden of personal suffering and societal cost (7) . Overall, known risk factors account for only a small fraction of all cardiac defects. For some of these factors, such as rubella, effective primm)' prevention is available through timely vaccination (8) . For others, such as maternal diabetes mellitus, interventions are more complex and the results less certain (9) . A potential new avenue for the primary prevention of cardiac defects was suggested by the results of a randomized clinical trial which showed that maternal periconceptional use of supplemental multivitamins containing folic acid could reduce the occurrence of neural tube defects (10) . In that study, the risks for some other birth defects, including some types of heart defects, appeared to be decreased. Subsequently, Botto et a1.(11) and Shaw et a1. (12) presented data from population-based case-control studies which showed that children of mothers who reported using multivitamins before and around the time of conception were at 40 percent less risk for a specific subset of cardiac anomalies, the outflow tract defects-e-although a subsequent case-control study of multivitamin use (30) and a study that evaluated folate intake in the year before conception (13) did not report similar findings. Cardiac outflow tract defects, however, represent only 10 percent of all cardiac defects (1-5). To assess the overall impact of multivitamin use on cardiac defects, we extended our analysis of a population-based case-control study to other major groups of cardiac defects.
MATERIALS AND METHODS

Study design
We analyzed data from the Atlanta Birth Defects Case-Control· Study. In that study, information was gathered in 1982-1983 from parents of infants with birth defects (case infants) and parents of infants who did not have birth defects (control infants). Case infants were ascertained through the Metropolitan Atlanta Congenital Defects Program, a populationbased registry that ascertains cases of birth defects among babies born to mothers residing in the fivecounty metropolitan Atlanta, Georgia, area. The reg-istry staff actively ascertains structural birth defects among stillborn and liveborn infants whose defects are diagnosed during the first year of life. Sources of information include vital records, medical records from birthing hospitals, pediatric and specialty wards, and cytogenetic laboratories. All infants with birth defects ascertained through the Metropolitan Atlanta Congenital Defects Program and born between January 1, 1968, and December 31, 1980, were eligible for entrance into the Atlanta Birth Defects CaseControl Study. The control group was a 1 percent stratified random sample of babies without birth defects born during the same period who were frequencymatched to the case group by hospital of birth, calendar quarter of birth, and race. Details on the design and procedures of the Atlanta Birth Defects Case-Control Study have been published elsewhere (14, IS).
Case classification
We selected as case subjects all liveborn and stillborn infants with a cardiac defect (International Classification of Diseases, Ninth Revision, Clinical Modification (16) codes 745.00-747.49). On the basis of abstracted medical records, each case subject was assigned an anatomic diagnosis and an overall clinical diagnosis. To ensure that each case subject received a single anatomic diagnosis, we used the hierarchical classi fication (I) shown in table 1.
Each case subject was also given one of three mutually exclusive clinical diagnoses: I) isolated, if the cardiac defect was the only major anomaly present; 2) multiple, if the cardiac defect was part of a pattern of multiple congenital anomalies of unknown cause; or 3) syndromic, if the cardiac defect was part of a genetic or teratogenic syndrome (e.g., trisomy 21, trisomy 13, congenital rubella). Syndromic cases were excluded from further analysis.
Exposure assessment
We obtained information on a variety of exposures, including vitamin use, through telephone interviews. The complete questionnaire used has been published elsewhere (15) . The classification of multivitamin exposure was based on the mothers' responses to three questions: 1) "At any time during the period from 3 months before the pregnancy began through the first 3 months of the pregnancy, did you take any vitamins regularly, that is, at least three times a week?" 2) "What type of vitamins did you take? That is, were they multivitamins or were they a single vitamin like vitamin C or vitamin A?" 3) "In which months during this period did you take the vitamin(s)?" On the basis of their answers to these questions, we grouped moth-
ers into the following mutually exclusive groups: 1) nonusers, if they reported no regular use of multivitamins during the 6-month period from 3 months before pregnancy through the third month of pregnancy; 2) periconceptional users, if they reported regular multivitamin use during the entire 6-month period from 3 months before pregnancy through the third month of pregnancy; 3) early postconceptional users. if they reported regular multivitamin use from the first month of pregnancy through the third month of pregnancy; 4) late postconceptional users, if they reported regular multivitamin use from the second month of pregnancy through the third month of pregnancy: 5) other users, if they reported other or discontinuous patterns of multivitamin use; and 6) unknown/uncodable. Regular multivitamin use was defined as taking a multivitamin at least three times per week.
The major comparison groups of interest in this study consisted of mothers who used multivitamins throughout the sensitive period of heart development (group 2 above) and mothers who did not use multivitamins during that same period (group 1 above).
Relative risk estimation
We examined contingency tables for the main exposure variables and covariates to look for confounding by single factors and for interaction. We then constructed logistic regression models to estimate the aggregate contribution of potential confounders. Potential confounders included maternal education. race, age, smoking, alcohol use, diabetes, parity, hospital of birth, period of birth, chronic diseases, and fever (table 2) . Because of differences in the proportions of case and control infants by race, diabetes, and period of birth, we present risk estimates adjusted for these three variables. For defect groups with less than 10 cases, we provide unadjusted risk estimates.
We used SAS software (SAS Institute. Cary, North Carolina) to estimate relative risks and 95 percent confidence intervals. When a cell was empty (see table -l), we used StatXact software (Cytel Software Corporation, Cambridge, Massachusetts) to calculate exact confidence intervals.
RESULTS
The overall participation rate in the Atlanta Birth Defects Case-Control Study was 71 percent (3,0291 4,246) for mothers of control infants and 69 percent (4,92917,133) for mothers of infants with birth defects. Of the infants with birth defects, 1,049 had a cardiac defect. The participation rate was 68 percent among mothers of children with a cardiac defect (75 percent among White mothers, 55 percent among mothers of other races). Of the 1,049 cases of cardiac defects, 91 (9 percent) were diagnosed as a clinically recognized syndrome or a condition with a known cause (genetic or teratogenic) and were excluded from further analysis. The remaining 958 nonsyndromic cases formed the basis of this report.
The distribution of defects by cardiac diagnosis and clinical diagnosis is shown in table I. As expected. the most frequent specific diagnoses were septal defects, obstructive defects. and outflow tract defects. When we compared demographic characteristics and pregnancy histories of the mothers of case and control infants, we found that, although they were similar with regard to most factors, they differed with respect to mother's race, history of chronic illness, and period of infant's birth (table 2) . Specifically, compared with mothers of case infants, mothers of control infants were more likely to be White and to have delivered in the earlier years of the study. and less likely to have had a chronic disorder around the time of conception.
The pattern of use of multivitamin supplements among case and control mothers is summarized in table J. or the control mothers. 14.2 percent reported using multivitamins regularly during the periconceptional period. while 38.9 percent reported no use during the same period. We had only limited information on the specific brand or composition of the multivitamin supplements used by the women in the study, so we were unable to evaluate the effect of specific supplements or their individual components.
Overall, risk estimates from the stratified analyses and logistic regression models were quite similar to those of the unadjusted analyses. suggesting that there was little individual confounding or aggregate confounding. Table  4 shows the estimated risk of having a baby with a cardiac defect among periconceptional multivitamin users compared with nonusers. Periconceptional multivitamin use was associated with a 24 percent apparent reduction in risk for all heart defects combined (odds ratio (OR) = 0.76; 95 percent confidence interval (CI): 0.60, 0.97). This reduction was driven mainly by a statistically significant reduction in outflow tract defects and ventricular septal defects (54 percent and 39 percent reductions, respectively).
We also compared mothers who reported beginning multivitamin use during the second or third month of pregnancy, presumably after the formation of the cardiac structures in the embryonic heart (late postconceptionai users). with mothers who did hot take multivitamins. Among these women, multivitamin use was not associated with a decreased risk for • No regular use of multivitamins during the 6-month period from 3 months before pregnancy through the third month of pregnancy.
t Regular multivitamin use during the entire 6-month period from 3 months before pregnancy through the third month of pregnancy. + L-TGA. levo-transposition of the great arteries.
DISCUSSION
We found that women who reported using multivitamin supplements in the periconceptional period were at significantly lower risk of having babies with congenital heart defects than were women who reported not using multivitamins. The apparent risk reduction was specific for some cardiac defects, but not all, and was strongest for outflow tract and ventricular septal defects. The timing of multivitamin use appeared to be critical. in that the apparent risk reduction was evident for use around the time of conception or early in the first month of pregnancy, but not for use starting during the second or third month of pregnancy.
In interpreting these findings, one should take into account the limitations and strengths of the study. Because participation was incomplete, selection bias cannot be ruled out. Participation differed between races, and we adjusted for this factor in the analysis. The potential for differential recall or reporting between mothers of case and control infants is also of concern, particularly because of the long time between pregnancy and interview. Other studies in which exposures, reported after the birth of a baby were compared with information obtained from prenatal obstetric records (17) or interviews conducted during the pregnancy (l8, 19) showed no major differences in the direction and strength of the detected associations. Although this does not necessarily mean that recall bias does not exist, it suggests that its effect, if present, may be small. Even in the absence of systematic biases, other factors that are associated with multivitamin use, and not multivitamin use in itself, may account for the findings. For example. periconceptional multivitamin users may differ from nonusers in ways other than multivitamin use, such as in the levels of micronutrients they obtain from natural or fortified foods. We did explore the effect of and then control for several maternal and demographic factors on which we had some information. The results did not differ appreciably from those of the unadjusted analysis, which suggests that there was little individual or aggregate confounding. Our ability to examine the effects of specific vitamins was limited by the lack of data on brand or composition. Finally, these results may have arisen by chance alone.
A major strength of the study is the fact that it was population-based. Case infants were actively ascertained through multiple sources from a geographically Maternal Multivitamin Use and Cardiac Defects 883 defined residential population, and control infants were selected through a stratified random sample to accurately represent the population from which the case group had been derived. In addition, the comparability of reports from case and control mothers was enhanced by the use of a structured interview, which covered a wide range of potential exposures, not only vitamin use.
We believe that this is the first population-based case-control study to have examined the association between multivitamin use and a wide spectrum of major cardiac defects ( figure 1 ). An overall reduced risk for cardiac defects was reported in a randomized clinical trial that was designed to study the effect of maternal periconceptional multivitamin use on the occurrence of neural tube defects (10) . In that study, the children of women who used a multivitamin supplement during the periconceptional period had a 52 percent reduced risk for all heart defects combined, in comparison with women who used a trace-element supplement.
Specifically, are consistent with the pattern of risk reduction seen in the clinical trial, although the overall risk reduction appeared to be lower in our study (24 percent) than in the randomized trial (52 percent). Two populationbased case-control studies (12, 13) , as well as a previous report from our group (II), limited their analysis to one particular group Of cardiac defects, the cardiac outflow tract defects, which account for approximately 10 percent of all cardiac defects. One of these studies (12) found a protective effect associated with periconceptional multivitamin use, while the other (13), which examined folic acid consumption before pregnancy, did not. A hospital-based case-control study (30) did not show a reduced risk of outflow tract and ventricular septal defects associated with multivitamin use. A relation between maternal vitamin consumption and cardiac defect occurrence has also been found in animal studies. In particular, folic acid-deficient rats have been reported to produce offspring with a range of cardiac defects, mostly ventricular septal defects and defects of the outflow tract and great vessels (20. 21). In addition, increased levels of homocysteine.
which may be a consequence of folic acid deficiency or abnormalities of the metabolism of folic acid and vitamin B 12, were shown to induce cardiac defects and neural tube defects in chick embryos (22) . This last study, which shows how a teratogen can induce both cardiac and neural tube defects, is particularly intriguing, because two case-control studies, one from our group (11, 23) and another from the California Birth Defects Monitoring Program (12, 24) , have reported an association between maternal multivitamin use and a reduction in both neural tube defects and a subset of cardiac defects. (30) . 'All heart defects,' all congenital heart defects combined.
reduction for neural tube defects depended on the timing of multivitamin use, in a manner similar to that which we describe for cardiac defects (23) . These similarities suggest that neural tube defects and some cardiac defects may be influenced by similar genetic or environmental factors. To date, genetic research has focused on neural tube defects, mainly because the protective effect of multivitamins and folic acid is more established and because researchers are uncovering growing evidence that polymorphisms of genes involved in the metabolism of folate and homocysteine may indeed playa role in modifying risk for neural tube defects (25) (26) (27) (28) (29) (30) . These findings, collectively. suggest that it may be fruitful to study such genetic variants in relation to cardiac defects, particularly outflow tract and ventricular septal defects. At the same time, further epidemiologic studies designed to confirm and extend our findings are warranted, because of the potential public health impact these findings may have. These studies might include an intervention or a randomized clinical trial for testing whether multivitamin use may be effective for primary prevention of at least some cardiac defects.
